adc therapeutics s.a. - ADCT
ADCT
Close Chg Chg %
1.94 0.05 2.32%
Closed Market
1.99
+0.05 (2.32%)
Volume: 513.16K
Last Updated:
Nov 22, 2024, 3:59 PM EDT
Company Overview: adc therapeutics s.a. - ADCT
ADCT Key Data
| Open $1.94 | Day Range 1.86 - 2.00 |
| 52 Week Range 0.69 - 6.00 | Market Cap $187.58M |
| Shares Outstanding 96.69M | Public Float 77.83M |
| Beta 1.60 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.40 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 439.79K |
ADCT Performance
| 1 Week | -16.74% | ||
| 1 Month | -32.54% | ||
| 3 Months | -35.18% | ||
| 1 Year | 170.01% | ||
| 5 Years | N/A |
ADCT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About adc therapeutics s.a. - ADCT
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
ADCT At a Glance
ADC Therapeutics SA
Biopôle
Epalinges, Vaud 1066
| Phone | 41-212-653-02-00 | Revenue | 69.56M | |
| Industry | Pharmaceuticals: Major | Net Income | -240,053,000.00 | |
| Sector | Health Technology | Employees | 162 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
ADCT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.95 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.115 |
| Enterprise Value to Sales | -0.267 |
| Total Debt to Enterprise Value | -6.695 |
ADCT Efficiency
| Revenue/Employee | 429,370.37 |
| Income Per Employee | -1,481,808.642 |
| Receivables Turnover | 2.762 |
| Total Asset Turnover | 0.157 |
ADCT Liquidity
| Current Ratio | 4.97 |
| Quick Ratio | 4.731 |
| Cash Ratio | 4.117 |
ADCT Profitability
| Gross Margin | 91.667 |
| Operating Margin | -236.318 |
| Pretax Margin | -282.288 |
| Net Margin | -345.112 |
| Return on Assets | -54.314 |
| Return on Equity | N/A |
| Return on Total Capital | 1,005.584 |
| Return on Invested Capital | -287.158 |
ADCT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -521.016 |
| Total Debt to Total Assets | 35.057 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -514.871 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Adc Therapeutics S.a. - ADCT
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 33.92M | 209.91M | 69.56M | |
Sales Growth
| - | -100.00% | +518.89% | -66.86% | |
Cost of Goods Sold (COGS) incl D&A
| 1.97M | 3.97M | 6.83M | 5.80M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.97M | 2.63M | 2.33M | 3.27M | |
Depreciation
| 1.93M | 2.50M | 2.21M | 3.27M | |
Amortization of Intangibles
| - | 47.00K | 129.00K | 118.00K | |
COGS Growth
| - | +101.47% | +71.96% | -15.16% | |
Gross Income
| (1.97M) | 29.94M | 203.08M | 63.76M | |
Gross Income Growth
| - | +1,618.46% | +578.19% | -68.60% | |
Gross Profit Margin
| - | +88.29% | +96.75% | +91.67% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 216.49M | 291.30M | 326.12M | 228.14M | |
Research & Development
| 139.71M | 155.53M | 185.50M | 127.13M | |
Other SG&A
| 76.78M | 135.77M | 140.62M | 101.01M | |
SGA Growth
| +82.79% | +34.55% | +11.95% | -30.04% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 47.20M | (34.89M) | 2.47M | (3.86M) | |
EBIT after Unusual Expense
| (265.66M) | (226.46M) | (125.51M) | (160.52M) | |
Non Operating Income/Expense
| 256.00K | 116.00K | 17.86M | 10.49M | |
Non-Operating Interest Income
| 832.00K | 66.00K | 17.97M | 10.54M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 4.93M | 18.49M | 36.92M | 46.33M | |
Interest Expense Growth
| +3,057.69% | +275.31% | +99.72% | +25.46% | |
Gross Interest Expense
| 4.93M | 18.49M | 36.92M | 46.33M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (270.33M) | (244.83M) | (144.58M) | (196.35M) | |
Pretax Income Growth
| -133.24% | +9.43% | +40.95% | -35.81% | |
Pretax Margin
| - | -721.86% | -68.88% | -282.29% | |
Income Tax
| 327.00K | (21.48M) | 1.14M | 38.17M | |
Income Tax - Current - Domestic
| - | 327.00K | 4.57M | 1.85M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | (26.05M) | (708.00K) | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | 935.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (246.29M) | (230.03M) | (155.80M) | (240.05M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (246.29M) | (230.03M) | (155.80M) | (240.05M) | |
Net Income Growth
| -111.44% | +6.60% | +32.27% | -54.08% | |
Net Margin Growth
| - | -678.20% | -74.22% | -345.11% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (246.29M) | (230.03M) | (155.80M) | (240.05M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (246.29M) | (230.03M) | (155.80M) | (240.05M) | |
EPS (Basic)
| -3.7653 | -2.9972 | -1.9935 | -2.9378 | |
EPS (Basic) Growth
| -116.16% | +20.40% | +33.49% | -47.37% | |
Basic Shares Outstanding
| 65.41M | 76.75M | 78.15M | 81.71M | |
EPS (Diluted)
| -3.7653 | -2.9972 | -1.9935 | -2.9378 | |
EPS (Diluted) Growth
| -116.16% | +20.40% | +33.49% | -47.37% | |
Diluted Shares Outstanding
| 65.41M | 76.75M | 78.15M | 81.71M | |
EBITDA
| (216.49M) | (258.72M) | (120.72M) | (161.11M) | |
EBITDA Growth
| -86.47% | -19.51% | +53.34% | -33.46% | |
EBITDA Margin
| - | -762.82% | -57.51% | -231.62% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 8.40 | |
| Number of Ratings | 6 | Current Quarters Estimate | -0.428 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -1.703 | |
| Last Quarter’s Earnings | -0.42 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.94 | Next Fiscal Year Estimate | -1.498 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 1 | 6 | 6 |
| Mean Estimate | -0.43 | -0.48 | -1.70 | -1.50 |
| High Estimates | -0.28 | -0.48 | -1.41 | -1.14 |
| Low Estimate | -0.51 | -0.48 | -1.87 | -1.89 |
| Coefficient of Variance | -20.16 | N/A | -10.02 | -21.15 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Adc Therapeutics S.a. - ADCT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Adc Therapeutics S.a. - ADCT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 4, 2024 | Redmile Group LLC | 15,669,217 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.81 per share | 44,030,499.77 |
| Jul 4, 2024 | Redmile Group LLC | 12,995,040 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.81 per share | 36,516,062.40 |
| Jun 19, 2024 | Ron Squarer Director | 80,663 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.89 per share | 233,116.07 |
| Jun 19, 2024 | Jean Pierre Bizzari Director | 79,502 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.89 per share | 229,760.78 |
| Jun 19, 2024 | Victor Sandor Director | 80,886 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.89 per share | 233,760.54 |
| Jun 19, 2024 | Viviane Monges Director | 106,627 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.89 per share | 308,152.03 |
| Jun 19, 2024 | Robert W. Azelby Director | 53,005 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.89 per share | 153,184.45 |
| Jun 19, 2024 | Thomas Pfisterer Director | 213,900 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.89 per share | 618,171.00 |
| Jun 19, 2024 | Peter Hug Director | 182,644 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $2.89 per share | 527,841.16 |
| May 10, 2024 | Ameet Mallik Chief Executive Officer; Director | 1,167,348 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $4.48 per share | 5,229,719.04 |
| Feb 14, 2024 | Redmile Group LLC | 100,000 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 100,000 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 93,424 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 53,900 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 50,000 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 100,000 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 100,000 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 50,000 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 28,652 | Open market or private purchase of non-derivative security | 0.00 |
| Feb 14, 2024 | Redmile Group LLC | 150,000 | Open market or private purchase of non-derivative security | 0.00 |